While TSCM cells make up a small percentage of T cells derived from cancer patients, genetically modifying these cells using qPB followed by CAR-T cell expansion with qBT resulted in enrichment of TSCM populations as high as >80% in both the CD4+ and CD8+ CAR+ T cell populations. The gene discussed is CD8A; the disease is cancer.